These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30804716)

  • 21. Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection.
    Miyasaka A; Yoshida Y; Murakami A; Hoshino T; Sawara K; Numao H; Takikawa Y
    Health Sci Rep; 2022 Mar; 5(1):e458. PubMed ID: 35024454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis c virus and chronic kidney disease.
    Khan MU; Mahmoud MI; Butt AA
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):579-590. PubMed ID: 32613874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease.
    Fabrizi F; Cerutti R; Messa P
    Pathogens; 2021 Oct; 10(11):. PubMed ID: 34832537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.
    Fabrizi F; Tripodi F; Cerutti R; Nardelli L; Alfieri CM; Donato MF; Castellano G
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing hepatitis C therapy failures and chronic kidney disease.
    Fabrizi F; Messa P
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1135-1142. PubMed ID: 30309263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.
    Kaya M; Nakamura K; Sugiyama K; Kinae A; Yamaguchi H; Ukita H; Odagiri K; Ujiie C; Kato J; Kageyama F; Nagura M; Matsushita K; Sugiue K; Ishida H; Endo S; Suzuki T
    J Clin Pharm Ther; 2022 Jul; 47(7):940-947. PubMed ID: 35229326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.
    Roth D; Bloom RD; Molnar MZ; Reese PP; Sawinski D; Sise ME; Terrault NA
    Am J Kidney Dis; 2020 May; 75(5):665-683. PubMed ID: 32279907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
    Gao LH; Nie QH; Zhao XT
    Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in hepatitis C virus management in chronic kidney disease.
    Cohen-Bucay A; Francis JM; Gordon CE
    Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):493-500. PubMed ID: 34054074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients.
    Sise ME; Chute DF; Gustafson JL; Wojciechowski D; Elias N; Chung RT; Williams WW
    Hemodial Int; 2018 Apr; 22 Suppl 1():S71-S80. PubMed ID: 29694722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
    Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.
    Corson M; Moch A; Saab S
    Gastroenterol Hepatol (N Y); 2018 May; 14(5):280-285. PubMed ID: 29991935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
    Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
    Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
    Kikuchi K
    Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).
    Minutolo R; Aghemo A; Chirianni A; Fabrizi F; Gesualdo L; Giannini EG; Maggi P; Montinaro V; Paoletti E; Persico M; Perticone F; Petta S; Puoti M; Raimondo G; Rendina M; Zignego AL; ; ; ;
    J Nephrol; 2018 Oct; 31(5):685-712. PubMed ID: 30255440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report.
    Cuvelier S; Van Caeseele P; Kadatz M; Peterson K; Sun S; Dodd N; Werestiuk K; Koulack J; Nickerson P; Ho J
    Can J Kidney Health Dis; 2021; 8():20543581211033496. PubMed ID: 34367648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).
    Minutolo R; Aghemo A; Chirianni A; Fabrizi F; Gesualdo L; Giannini EG; Maggi P; Montinaro V; Paoletti E; Persico M; Perticone F; Petta S; Puoti M; Raimondo G; Rendina M; Zignego AL; ; ; ;
    Intern Emerg Med; 2018 Dec; 13(8):1139-1166. PubMed ID: 30255464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.
    Bruchfeld A; Lindahl K
    Semin Dial; 2019 Mar; 32(2):135-140. PubMed ID: 30475421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.